theory clinical_107_1
imports Main

begin

typedecl entity
typedecl event

consts
  HER2Mutation :: "entity ⇒ bool"
  V777L :: "entity ⇒ bool"
  Overexpression :: "entity ⇒ entity ⇒ bool"
  TrastuzumabResistance :: "entity ⇒ bool"
  Assay :: "entity ⇒ bool"
  ColonyFormation :: "entity ⇒ bool"
  CancerCellLine :: "entity ⇒ bool"
  InAssay :: "entity ⇒ entity ⇒ bool"
  ByAssay :: "entity ⇒ entity ⇒ bool"
  OfLine :: "entity ⇒ entity ⇒ bool"
  Tumors :: "entity ⇒ bool"
  Portion :: "entity ⇒ entity ⇒ bool"
  Develop :: "entity ⇒ bool"
  Resistance :: "entity ⇒ bool"
  AntiHER2Therapy :: "entity ⇒ bool"
  ToTherapy :: "entity ⇒ entity ⇒ bool"
  Ultimately :: "entity ⇒ bool"
  Patient :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  Trastuzumab :: "entity ⇒ bool"
  Benefit :: "entity ⇒ bool"
  FromTreatment :: "entity ⇒ entity ⇒ bool"
  WithTreatment :: "entity ⇒ entity ⇒ bool"

(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)
axiomatization where
  explanation_1: "∃x y z w v e. HER2Mutation x ∧ V777L x ∧ Overexpression y x ∧ TrastuzumabResistance z ∧ Assay w ∧ ColonyFormation w ∧ CancerCellLine v ∧ InAssay z w ∧ ByAssay z w ∧ OfLine w v"

(* Explanation 2: A portion of tumors, however, ultimately develop resistance to anti-HER2 antibody therapy. *)
axiomatization where
  explanation_2: "∃x y z e. Tumors x ∧ Portion y x ∧ Develop z ∧ Resistance z ∧ AntiHER2Therapy e ∧ ToTherapy z e ∧ Ultimately y"

(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)
axiomatization where
  explanation_3: "∃x y z e. Patient x ∧ Treatment y ∧ Trastuzumab z ∧ Benefit e ∧ FromTreatment e y ∧ WithTreatment z y"

theorem hypothesis:
  assumes asm: "Patient x"
  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)
  shows "∃x y z e. Patient x ∧ Resistance y ∧ Trastuzumab z ∧ Develop e ∧ Agent e x ∧ Patient e y ∧ ToTherapy y z"
  sledgehammer
  oops

end
